Keywords: Bayer Schering, Micromet, BiTE antibody, Licensing, Solid tumors
Bayer Schering collaborates with Micromet on novel approach to cancer therapy in up to $429 million deal
Article | 2 December 2009
Bayer Schering Pharma of Germany says it will develop a new BiTE antibody for the treatment of solid tumors in collaboration with US biopharmaceutical company Micromet in a deal worth a potential 285 million euros ($429 million) in milestone payments to the latter, whose shares jumped 4% to $7.1 shortly after US stock markets opened today.
In January, the two companies had entered into an option, license and collaboration agreement. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
